SPLENIC MARGINAL ZONE LYMPHOMA
Clinical trials for SPLENIC MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SPLENIC MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for SPLENIC MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to control rare blood cancer
Disease control OngoingThis study is testing the safety and effectiveness of combining two existing drugs, ibrutinib and rituximab, for people newly diagnosed with a slow-growing blood cancer called marginal zone lymphoma. The trial will enroll 175 adults who have not yet received any chemotherapy or i…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo trial aims to keep rare lymphoma at bay longer
Disease control OngoingThis study is for adults with a rare, slow-growing blood cancer called splenic marginal zone lymphoma (SMZL) who have not yet had treatment. It aims to see if taking two drugs together (rituximab and zanubrutinib) is more effective at controlling the cancer and preventing it from…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE3 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Scientists test powerful new drug cocktail to fight back against tough lymphomas
Disease control OngoingThis early-stage study is testing a new combination of three drugs for people whose non-Hodgkin's lymphoma has come back after prior treatment. The main goal is to find the safest and most effective dose of a new pill (PCI-32765) when given with two existing drugs (rituximab and …
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Engineered immune cells target cancer in groundbreaking lymphoma trial
Disease control OngoingThis early-phase study is testing a new type of cell therapy for patients with high-risk or returning B-cell non-Hodgkin lymphoma. After receiving a stem cell transplant, patients get an infusion of their own immune cells that have been genetically modified in a lab to better fin…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New strategy aims to tame dangerous virus after cancer transplant
Disease control OngoingThis study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC